kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - kystinen fibroosi - muut hengitysteiden tuotteet - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
levosimendan altan 2.5 mg/ml infuusiokonsentraatti, liuosta varten
altan pharma ltd - levosimendan - infuusiokonsentraatti, liuosta varten - 2.5 mg/ml - levosimendaani
sporanox 100 mg kapseli, kova
janssen-cilag oy - itraconazole - kapseli, kova - 100 mg - itrakonatsoli
sporanox 10 mg/ml oraaliliuos
janssen-cilag oy - itraconazole - oraaliliuos - 10 mg/ml - itrakonatsoli
gaviscon oraalisuspensio
nordic drugs ab - aluminium hydroxide gel, calcium carbonate, sodium alginate, sodium hydrogen carbonate - oraalisuspensio - algiinihappo
gaviscon purutabletti
nordic drugs ab - alginic acid, aluminium hydroxide gel, dried, sodium hydrogen carbonate - purutabletti - algiinihappo
robinul 0.2 mg/ml injektioneste, liuos
viatris oy - glycopyrronium bromide - injektioneste, liuos - 0.2 mg/ml - glykopyrroniumbromidi
ranixal 150 mg tabletti, kalvopäällysteinen
ratiopharm gmbh - ranitidini hydrochloridum - tabletti, kalvopäällysteinen - 150 mg - ranitidiini
ranixal 300 mg tabletti, kalvopäällysteinen
ratiopharm gmbh - ranitidini hydrochloridum - tabletti, kalvopäällysteinen - 300 mg - ranitidiini
paxlovid
pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.